Intuitive Surgical, Inc. vs Rocket Lab USA Inc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Intuitive Surgical, Inc. is far larger — about 3.4× Rocket Lab USA Inc's market cap, and Rocket Lab USA Inc is more actively traded (22,892,581 versus 2,529,814). Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Rocket Lab USA Inc for 29 Days on average.
| ISRG | RKLB | |
|---|---|---|
Market Cap | $146.76B | $43.74B |
Volume | 2,529,814 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $592.85 | $150.23 |
52-Week Low | $332.02 | $39.48 |
Typical Hold Time | 84 Days | 29 Days |
Enterprise Value | $141.54B | $41.57B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.80, and has shown consistent revenue growth, reaching $10.06B in 2025. Analyst consensus is strongly bullish with a $480.78 price target, though the stock faces headwinds from slower procedure growth in some markets.
The outlook for ISRG remains positive due to its dominant position in robotic surgery, expanding international presence, and high recurring revenue. Key risks include competitive pressures, regulatory hurdles, and economic sensitivity affecting procedure volumes. With solid fundamentals and analyst support, the stock offers growth potential, but investors should monitor execution against these risks.
Rocket Lab (RKLB) trades at $68.40, down 4.89% today, amid bearish technical signals despite positive business developments. The company recently secured its largest-ever commercial Electron launch contract with Synspective for 20 missions, expanding its backlog to over 100 launches. Fundamentally, RKLB shows strong revenue growth with $602 million in 2025 and projected $769 million in 2026, though it remains unprofitable with negative margins. Analyst sentiment remains overwhelmingly bullish with 16 buy ratings and a $107 consensus price target, representing significant upside potential from current levels.
Rocket Lab presents a high-risk, high-reward opportunity with substantial growth potential in the expanding space economy offset by persistent losses and competitive threats from SpaceX. The company's expanding launch backlog and Neutron rocket development provide long-term catalysts, but investors must weigh the premium valuation against ongoing cash burn and execution risks in a capital-intensive industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →